Bio Green Med Solution, Inc. 10-Q

Item 5. Other Information None. Item 6. Exhibits Exhibit Number Description ​ ​ ​ ​ ​ ​ 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a) As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a) As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2* Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101* The following materials from Cyclacel Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2021, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements. ​ ​ ​ 27 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned. ​ ​ ​ ​ ​ CYCLACEL PHARMACEUTICALS, INC. ​ ​ ​ ​ Date: May 14, 2021 ​ By: /s/ Paul McBarron ​ ​ ​ Paul McBarron ​ ​ ​ Chief Operating Officer, Chief Financial Officer and Executive Vice President, Finance ​ 28